[{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"9029b63b-49b7-4f5b-bf2d-d1dd5f6be242","acronym":"","url":"https://clinicaltrials.gov/study/NCT04006769","created_at":"2021-01-18T19:41:21.824Z","updated_at":"2024-07-02T16:35:32.887Z","phase":"Phase 1","brief_title":"Entacapone Combination With Imatinib for Treatment of GIST","source_id_and_acronym":"NCT04006769","lead_sponsor":"Xiangya Hospital of Central South University","biomarkers":" KIT • FTO","pipe":" | ","alterations":" KIT mutation • KIT expression • FTO expression","tags":["KIT • FTO"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT expression • FTO expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 10/30/2020","start_date":" 10/30/2020","primary_txt":" Primary completion: 08/31/2022","primary_completion_date":" 08/31/2022","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2023-10-18"},{"id":"0b91480a-55cb-4309-8f88-b64e9e161528","acronym":"GIST-TEN","url":"https://clinicaltrials.gov/study/NCT05009927","created_at":"2021-08-18T15:53:39.355Z","updated_at":"2024-07-02T16:35:38.218Z","phase":"Phase 2","brief_title":"Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)","source_id_and_acronym":"NCT05009927 - GIST-TEN","lead_sponsor":"Centre Leon Berard","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/03/2022","start_date":" 01/03/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-01"},{"id":"983aaac7-64d1-4282-a35f-5f3da2b05623","acronym":"","url":"https://clinicaltrials.gov/study/NCT01806571","created_at":"2021-01-18T08:00:32.931Z","updated_at":"2024-07-02T16:35:46.814Z","phase":"Phase 2","brief_title":"Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01806571","lead_sponsor":"Mayo Clinic","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • nilotinib • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/12/2015","start_date":" 03/12/2015","primary_txt":" Primary completion: 07/31/2017","primary_completion_date":" 07/31/2017","study_txt":" Completion: 11/30/2019","study_completion_date":" 11/30/2019","last_update_posted":"2023-05-31"},{"id":"e81d8f6a-f54e-4fa4-81cb-20645d7fecb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00716820","created_at":"2021-01-18T02:41:02.397Z","updated_at":"2024-07-02T16:35:51.237Z","phase":"","brief_title":"Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).","source_id_and_acronym":"NCT00716820","lead_sponsor":"Pfizer","biomarkers":" KIT • CYP3A4","pipe":" | ","alterations":" KIT mutation • KIT expression","tags":["KIT • CYP3A4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 472","initiation":"Initiation: 04/01/2008","start_date":" 04/01/2008","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2023-04-06"},{"id":"a7bee12a-ff64-45e1-9308-01446bcecefe","acronym":"","url":"https://clinicaltrials.gov/study/NCT00028002","created_at":"2021-01-17T23:59:38.802Z","updated_at":"2024-07-02T16:36:39.598Z","phase":"Phase 2","brief_title":"Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT00028002","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/31/2002","start_date":" 03/31/2002","primary_txt":" Primary completion: 01/28/2009","primary_completion_date":" 01/28/2009","study_txt":" Completion: 01/28/2009","study_completion_date":" 01/28/2009","last_update_posted":"2020-10-26"},{"id":"04b46744-762d-4882-a99b-dba90748a1b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00509093","created_at":"2021-01-18T01:49:51.826Z","updated_at":"2024-07-02T16:36:48.304Z","phase":"Phase 2","brief_title":"Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy","source_id_and_acronym":"NCT00509093","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 10/01/2008","start_date":" 10/01/2008","primary_txt":" Primary completion: 05/09/2014","primary_completion_date":" 05/09/2014","study_txt":" Completion: 04/09/2015","study_completion_date":" 04/09/2015","last_update_posted":"2020-03-17"},{"id":"8aebf424-8909-4895-a7e6-e2f46f58b8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02642016","created_at":"2021-01-18T12:51:11.933Z","updated_at":"2024-07-02T16:36:58.921Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02642016","lead_sponsor":"Celldex Therapeutics","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT positive • PDGFRA D842V • KIT expression","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT positive • PDGFRA D842V • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-0158"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/30/2018","primary_completion_date":" 01/30/2018","study_txt":" Completion: 06/04/2019","study_completion_date":" 06/04/2019","last_update_posted":"2019-06-12"},{"id":"57c81b9c-1589-48e6-af8a-b8850f1fe404","acronym":"","url":"https://clinicaltrials.gov/study/NCT03923400","created_at":"2021-01-18T19:18:05.505Z","updated_at":"2024-07-02T16:37:00.373Z","phase":"","brief_title":"Jejunoileal vs Gastric GIST in the Era of Imatinib.","source_id_and_acronym":"NCT03923400","lead_sponsor":"Hospital Universitario Virgen de la Arrixaca","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT positive • PDGFRA mutation • KIT expression","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT positive • PDGFRA mutation • KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 77","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 01/31/2017","primary_completion_date":" 01/31/2017","study_txt":" Completion: 01/31/2017","study_completion_date":" 01/31/2017","last_update_posted":"2019-04-22"},{"id":"6a70d320-4efb-4145-a025-00237e18ff01","acronym":"","url":"https://clinicaltrials.gov/study/NCT00027586","created_at":"2021-01-17T23:59:26.262Z","updated_at":"2024-07-02T16:37:05.695Z","phase":"Phase 2","brief_title":"Imatinib Mesylate in Treating Patients With Metastatic Melanoma","source_id_and_acronym":"NCT00027586","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1","pipe":" | ","alterations":" KIT expression","tags":["ABL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 09/01/2001","start_date":" 09/01/2001","primary_txt":" Primary completion: 01/01/2005","primary_completion_date":" 01/01/2005","study_txt":" Completion: 01/01/2005","study_completion_date":" 01/01/2005","last_update_posted":"2018-10-31"},{"id":"97d359bc-0674-4d9f-a5d6-11b5987b3936","acronym":"","url":"https://clinicaltrials.gov/study/NCT00859937","created_at":"2021-01-18T03:16:42.805Z","updated_at":"2024-07-02T16:37:11.327Z","phase":"Phase 2","brief_title":"Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors","source_id_and_acronym":"NCT00859937","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression • KIT overexpression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression • KIT overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 03/16/2009","start_date":" 03/16/2009","primary_txt":" Primary completion: 01/30/2013","primary_completion_date":" 01/30/2013","study_txt":"","study_completion_date":"","last_update_posted":"2018-04-20"},{"id":"9e3d8f1b-a521-4353-a085-fa222ff26efb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02680951","created_at":"2021-01-18T13:04:24.331Z","updated_at":"2024-07-02T16:37:11.385Z","phase":"Phase 1","brief_title":"Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia","source_id_and_acronym":"NCT02680951","lead_sponsor":"Emory University","biomarkers":" KIT • STAT3","pipe":" | ","alterations":" KIT expression","tags":["KIT • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • cytarabine • idarubicin hydrochloride • fludarabine IV • Depocyte (liposomal cytarabine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/15/2017","primary_completion_date":" 12/15/2017","study_txt":" Completion: 12/15/2017","study_completion_date":" 12/15/2017","last_update_posted":"2018-04-19"},{"id":"5ec330f3-fcea-4919-92db-02c9bd3c7c0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00867113","created_at":"2021-01-18T03:18:31.209Z","updated_at":"2024-07-02T16:37:13.019Z","phase":"Phase 2","brief_title":"Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)","source_id_and_acronym":"NCT00867113","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 91","initiation":"Initiation: 07/22/2009","start_date":" 07/22/2009","primary_txt":" Primary completion: 12/20/2016","primary_completion_date":" 12/20/2016","study_txt":" Completion: 12/20/2016","study_completion_date":" 12/20/2016","last_update_posted":"2018-03-14"},{"id":"23e6ea0a-e3e2-4fd3-b084-8332cba9dab5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00455559","created_at":"2021-01-18T01:36:55.198Z","updated_at":"2024-07-02T16:37:13.730Z","phase":"Phase 2","brief_title":"Ph II Study of Perifosine Plus Gleevec for Patients With GIST","source_id_and_acronym":"NCT00455559","lead_sponsor":"AEterna Zentaris","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • perifosine (D21266)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2006","start_date":" 08/01/2006","primary_txt":" Primary completion: 11/01/2010","primary_completion_date":" 11/01/2010","study_txt":" Completion: 10/01/2011","study_completion_date":" 10/01/2011","last_update_posted":"2018-02-22"}]